



G Medical Innovations Holdings Ltd
ARBN 617 204 743

ASX Announcement

23 December 2019

CHANGE OF DIRECTOR INTEREST

Mobile and e-Health company **G Medical Innovations (ASX: GMV)** (“**G Medical**” or the “**Company**”) provides shareholders with an update on the recent change in directors interest following the sale of shares by CEO and Managing Director, Dr Yacov Geva.

The sale of 11,800,000 shares to sophisticated, professional and institutional investors was facilitated to repay a portion of a personal loan provided by JP Morgan to Dr Geva. The proceeds of this loan were previously utilised by Dr Geva to provide a loan to G Medical to fund inventory, medical devices and working capital requirements.

Dr Geva remains G Medical’s largest shareholder as it aggressively expands in the United States and other key markets. In addition to his significant shareholding, Dr Geva’s ongoing commitment to G Medical is further reflected by the US\$10m unsecured loan provided to the Company (refer ASX announcement: 31 October 2018) by Dr Geva.

Please refer enclosed Appendix 3Y – change of director interest form.

Authorised for release by Dr Yacov Geva, CEO and Managing Director of the Company.

Ends

Released through: Henry Jordan, Six Degrees Investor Relations: +61 (0) 431 271 538

About G Medical Innovations

G Medical (**ASX: GMV**) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and e-health solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit www.gmedinnovations.com

About G Medical products:

G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals.

The ‘Prizma’ Medical Smartphone Case is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The ‘Prizma’ allows consumers to turn

their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical's Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity G Medical Innovations Holdings Limited
ARBN 617 204 743

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Yacov Geva
Date of last notice	14 October 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	<ol style="list-style-type: none"> 1 Indirect 2 Indirect 3 Indirect 4 Indirect 5 Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	<ol style="list-style-type: none"> 1 Beneficial holding held through and registered in the name of Bank Julius Baer & Co Ltd 2 Beneficial holding held through custodian and registered in the name of HSBC Custody Nominees (Australia) Limited 3 Beneficial holding held through custodian and registered in the name of J P Morgan Nominees Australia Pty Limited 4 Beneficial holding held through custodian and registered in the name of Millinium Capital Managers Limited 5 Beneficial holding held through custodian and registered in the name of Monex Boom Securities (HK) Ltd
Date of change	17 December 2019

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<ol style="list-style-type: none"> 1 49,745,275 Class C Performance Rights 2 3,672,000 fully paid ordinary shares 3 193,778,322 fully paid ordinary shares 4 5,000,000 fully paid ordinary shares 5 24,239,490 fully paid ordinary shares
Class	Fully paid ordinary shares
Number acquired	<ol style="list-style-type: none"> 1. Nil 2. Nil 3. Nil 4. Nil 5. Nil
Number disposed	<ol style="list-style-type: none"> 1. Nil 2. Nil 3. 11,800,000 4. Nil 5. Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$785,000
No. of securities held after change	<ol style="list-style-type: none"> 1 49,745,275 Class C Performance Rights 2 3,672,000 fully paid ordinary shares 3 181,978,322 fully paid ordinary shares 4 5,000,000 fully paid ordinary shares 5 24,239,490 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	The sale of the shares to sophisticated, professional and institutional investors was facilitated to repay a portion of a personal loan provided by JP Morgan to Dr Geva

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.